Major depressive disorder (MDD) is known for its substantial clinical and suspected causal heterogeneity. It is characterised by low mood, psychomotor slowing, and increased levels of the personality trait neuroticism; factors which are also associated with schizophrenia (SCZ). It is possible that some cases of MDD may have a substantial genetic loading for SCZ. A sign of the presence of SCZ-like MDD sub-groups would be indicated by an interaction between MDD status and polygenic risk of SCZ on cognitive, personality and mood measures. In the current study, we hypothesised that higher SCZpolygenic risk would define larger MDD case-control differences in cognitive ability, and smaller differences in distress and neuroticism. Polygenic risk scores (PGRS) for SCZ and their association with cognitive variables, neuroticism, mood, and psychological distress were estimated in a large population-based cohort (Generation Scotland: Scottish Family Health Study, GS:SFHS). Individuals were divided into those with, and without, depression (n=2587 & n=16,764 respectively) to test whether there was an interaction between MDD status and schizophrenia risk. Replication was sought in UK Biobank (n=33,525). In both GS:SFHS and UK Biobank we found significant interactions between SCZ-PGRS and MDD status for measures of psychological distress and neuroticism. In both cohorts there was a reduction of case-control differences on a background of higher genetic risk of SCZ.
Introduction
Major depressive disorder (MDD) has a lifetime prevalence of approximately 16% and is a heritable and severely disabling psychiatric condition (1) . It is highly clinically heterogeneous, relying on diagnostic criteria that are fulfilled through the presence of an arbitrary threshold of symptoms that lack empirical validation. Further, individuals passing this threshold can have a very different combination of symptoms. As a likely consequence of causal heterogeneity, progress in our understanding of depression's underlying risk factors and biological mechanisms has been limited.
MDD is characterised by sustained negative affect, psychological distress and by differences in personality and behavioural traits, such as increased levels of the personality trait neuroticism (2) . People with MDD also manifest, on average, reduced executive function, attention, processing speed and working memory (3), but relatively preserved general cognitive ability (4) .
These behavioural and personality features are partly heritable, enduring features of illness that are often genetically correlated with liability to MDD (5-8). Notably however, these clinical and personality associations are not specific to MDD and also occur in other psychiatric disorders including schizophrenia (SCZ) (9-11).
Genetic factors account for ~37% of liability to MDD and depressive symptoms (12, 13) . Genome-wide association studies (GWAS) have indicated that ~30% of the heritability for MDD is accounted for by an additive polygenic genetic architecture, where risk is conferred by an accumulation of many alleles of small effect (14) . There is also a genetic overlap with other major psychiatric disorders, including SCZ (15) . For example, two papers have Stratifying depression by schizophrenia risk Whalley et al. 4 shown genetic correlation between MDD and SCZ using both genome-wide association analysis identifying shared risk loci (15) , or an approach estimating genetic correlation from sampled SNPs (16) . These findings have been interpreted as showing that there are genetic variants that raise liability to both MDD and SCZ. Recently, however, a second possibility has been proposed -that the genetic correlation between SCZ and MDD is caused not by pleiotropy, but by the misclassification of SCZ cases as MDD. This possibility has recently been tested using a novel method aimed at using genotype data to distinguish pleiotropy from heterogeneity, where early evidence suggested that some cases of SCZ may have been misclassified as MDD, though this did not reach significance in this proof of technique study (17) . If confirmed, this would imply that some cases of MDD would be a hidden 'forme fruste' of SCZ, or that some individuals with MDD may be on a trajectory towards SCZ, but have yet to manifest the clinical phenotype.
Effects of polygenic risk for SCZ have also been demonstrated on a number of related behavioural and cognitive phenotypes. It has been consistently demonstrated for example that polygenic risk for schizophrenia is associated with decreased cognitive ability in healthy control samples (18-21).
However, since most studies have examined these relationships in unaffected controls, it is unclear whether the associations between SCZ risk and behaviour/cognitive ability are ameliorated or magnified by the presence of depression. Clarifying this relationship is important because, if MDD consists of a subtype which is closely related to schizophrenia, then that subtype would be expected to show associations with behaviour and cognitive ability that resembled those of SCZ itself.
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In the current paper we sought to stratify depression using a continuous scale of SCZ polygenic risk score, hypothesising that case-control differences would depend on genetic risk for schizophrenia, in other words, that there would be a significant interaction between SCZ-PGRS and MDD status. We made two predictions, (1) based on the premise that deficits in cognition are greater in SCZ than in MDD, we first predicted that the high-SCZ-PGRS MDD case-control differences for cognitive variables would be greater compared to those with lower SCZ-PGRS scores.
(2) Since neuroticism and psychological distress differ to a greater extent in MDD than SCZ (22) we also predicted that SCZ-PGRS and MDD status interactions would be found for these variables, but that they would be the reverse direction to cognition (attenuated in those with high SCZ-PGRS). We sought to test these predictions in a population based cohort study, the Generation Scotland cohort: The Scottish Family Health Study sample (GH:SFHS) (23, 24). Replication of any significant findings was sought in UK Biobank.
Materials and Methods

Main Study Participants
Generation Scotland: the Scottish Family Health Study (GS:SFHS)
GS:SFHS is a family-and population-based cohort study. Individuals were recruited at random through general medical practices across Scotland. Initial data collection for GS:SFHS took place between February 2006 and March 2011. The complete study protocol has been described in detail elsewhere (23-25). Details of the mental health and related assessments are summarised below. Ethical approval was provided by NHS Tayside Research Ethics Committee (reference 05/S1401/89). Written consent for the use of data was obtained from all participants.
The full cohort consists of 23,690 individuals who were over 18 years at the time of recruitment and 21,516 of these attended the research clinic. The present study includes 19,351 individuals on whom genome-wide genotype data were available (demographic details presented in Table 1 ). Pedigree information was available for all participants, and this has subsequently been validated against estimates of relatedness estimated using genome-wide single nucleotide polymorphism (SNP) data on 19,995 individuals.
Assessment of MDD in GS:SFHS
MDD was diagnosed using the structured clinical interview for the Diagnostic someone because of the way you were feeling or acting?" If they answered yes to either of these questions (21.7% screened positive), they were asked to complete the SCID (26). If they answered no to both of these questions, they were assigned control status. Those who completed the SCID but did not meet the criteria for MDD or other major psychiatric disorder were also defined as controls. Individuals who declined to complete the screening questionnaire or the SCID had their MDD status set to missing. Individuals with a diagnosis of bipolar disorder were removed for the purposes of the current investigation. Table 2 . ambiguous SNPs were removed from the GS:SFHS dataset and the polygenic risk score for each individual was calculated using the cumulative sum of the number of each SNP allele multiplied by the log of the odds ratio for SCZ across their whole genome. Five SNP set scores were generated using pvalue threshold cut-offs of 1, 0.5, 0.1, 0.05 and 0.01. Our primary analyses concerned those SNPs from the PGC data that met a significance level of p=.5 consistent with previous studies (35). Findings for other thresholds are contained within Supplementary Material.
Cognitive assessment in GS:SFHS
Genotyping and Polygenic Profiling in GS:SFHS
Replication sample: UK Biobank
This study includes replication data from the UK Biobank Study . All test scores were scaled to a mean of zero and standard deviation of one. General cognitive ability (g) was estimated using the principal component analysis approach described above (30).
Measures of neuroticism and psychological distress in UK Biobank
In UK Biobank, participants completed the Neuroticism scale of the Eysenck Personality Questionnaire-Revised Short Form (EPQ-R Short Form) (37). As a measure of psychological distress UK Biobank participants undertook the Patient Health Questionnaire (PHQ) which is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
As in GS:SFHS scores were scaled to a mean of zero and standard deviation of one.
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Genotyping and Polygenic Profiling in UK Biobank
Details of the array design, genotyping, quality control and imputation have been described previously (38) . As in the main GS:SFHS analysis, current results focus on P<0.5.
Statistical Analysis
All analyses were conducted in ASReml-R (www.vsni.co.uk/software/asreml, version 3.0). Associations were examined between PGRSs for SCZ and cognition (cognitive factor 'g', and contributing tests), psychological distress (GHQ total), and neuroticism (from the Eysenck personality questionnaire) using mixed linear model association analysis in GS:SFHS. Age, age 2 , sex, four multidimensional scaling ancestry components and polygenic profile scores were entered as fixed effects. Since GS:SFHS is a family-based study,
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to control for relatedness family structure was fitted as a random effect by creating an inverse relationship matrix using pedigree kinship information. 
SCZ
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Results
Demographic, cognitive, trait-related features of MDD and PGRS scores in GS:SFHS.
Demographic details are presented in Table 1 for GS:SFHS. Thresholds for case-control group significance were defined as p<2x10 -5 . Groups defined according to depression status were significantly different in terms of sex, psychological distress (GHQ) and for neuroticism ( Table 1 ). The depression group scored higher on the latter two measures. Differences between the groups did not reach significance for the individual cognitive tests. MDD cases and controls also differed significantly on the SCZ PGRS score, with MDD individuals scoring higher.
Demographic details of individuals from UK Biobank included in the current study are presented in Supplementary Table 1 . There were significant differences between the groups in terms of age and gender (p<2x10 -5 ). The groups also differed according to psychological distress and neuroticism, with the MDD cases scoring higher than controls. Differences between the groups did not reach significance for the individual cognitive tests and MDD cases and controls differed significantly on the SCZ PGRS score, with MDD individuals scoring higher.
Interaction between MDD status and polygenic risk for schizophrenia, in
GS:SFHS and UK Biobank.
Results for tests of interaction are presented in Table 2 , GS:SFHS and UK Biobank) (see Table 3 ). There were no significant associations within the MDD groups for either measure, in either cohort (see Table 3 , Figures 1 a,b ). In terms of psychological distress the proportion of variance explained was 0.15% and 0.22% for control individuals, for GS:SFHS and UK Biobank respectively, and 0.02%, 0.01% for MDD cases. For measures of neuroticism values were 0.17% and 0.30% in controls and <0.01% in MDD cases (see Tables 3 and 4 and Figure 2 ). For the measure of processing speed in GS:SFHS there was a significant negative relationship in both controls and cases, but the MDD cases demonstrated greater effect size and greater variance explained (1.09%) versus that seen in control individuals (0.33%) (see Table 3 ). For both distress and neuroticism the SCZ-PGRS * MDD status interactions remained significant after modelling whether individuals were experiencing a current depressive episode at the time of assessment according to the SCID, and when modelling whether individuals were taking antidepressant medication at the time of assessment according to self-report, full details in supplementary material.
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Discussion
Consistent with our predictions we report larger MDD case-control differences in cognition in the context of higher SCZ-PGRS scores in GS:SFHS, although this was not replicated in UKB. We also found MDD case-control differences in neuroticism and distress that were attenuated by higher SCZ-PGRS scores.
Lastly, we demonstrate that the greatest variance explained for neuroticism and distress is higher in controls rather than in MDD cases, supporting the suggestion that the MDD group contains a more heterogeneous group comprising differing aetiological subtypes.
PGRS SCZ associations and interactions with cognition
Previous studies have consistently reported a negative relationship between cognitive function and SCZ-PGRS, indicating shared genetic risk between SCZ and deficits in cognition (18-20, 41). With the exception of one previous study where genetic loading for SCZ (based on proximal family history) was reported to have a substantial negative impact on neurocognition in mood disorder patients (42), we are not aware of any other studies examining this relationship in the context of MDD. In the current study, data from the four individual subtests that contributed to the general factor indicated a significant interaction between SCZ-PGRS and MDD case control status for the digit symbol coding test. This test is a measure of processing speed, which is known to be significantly impaired in SCZ patients, even in relation to other neuropsychological measures (43, 44). Within GS:SFHS, significant negative associations between SCZ-PGRS and processing speed were reported in both controls and MDD cases. In other words, individuals in GS:SFHS with
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MDD demonstrated greater deficits in tests of processing speed in those who had higher genetic loading for SCZ versus those at low risk. However, the lack of formal replication means these results should be viewed with caution.
PGRS SCZ associations and interactions with clinical and trait features
Neuroticism is considered to be a stable heritable trait (45) characterized by high tension, irritability, dissatisfaction, shyness, low mood and reduced selfconfidence (32). Psychological distress is a more generalised measure of psychiatric well-being or psychological health than a specific psychopathological categorisation. These two traits have been reported to share strong genetic links (7), and there has been considerable support for overlapping genetic risk factors affecting neuroticism and MDD (46). Direct links between genetic risk for schizophrenia and these measures however are less commonly reported than associations with cognitive deficits, as described above.
These measures demonstrated significant interaction effects between SCZ-PGRS and MDD case-control status, seen in both GS:SFHS and UK Biobank cohorts. In addition, the variance explained for these measures was greater in control individuals (~0.20%) than in MDD cases (~0.01%). We suggest that this may be attributable to the aetiologically diverse subgroups within MDD cases. The origins of these interactions were an attenuation of case-control differences on a background of higher genetic risk of SCZ, seen in both cohorts. Neuroticism and psychological distress may therefore be less closely related to the aetiology of depression in the context of high genetic risk for schizophrenia (see Fig 1) . It is, however, also possible that the absence of a similar gradient of effect in MDD cases could be due to the substantial effects of depression on distress and neuroticism, leading to a ceiling effect whereby the additional effect of SCZ-PGRS on these phenotypes is undetectable. However, we consider that this is unlikely since the variance of these measures are not in fact smaller in the MDD groups in comparison to the control group (which would be the case if there were ceiling effects, see Table 1 ), and so truncation of these scores at the extreme end seems unlikely.
Together, these findings suggest that depression on a background of high genetic risk for schizophrenia may represent a somewhat causally distinct form of the condition.
Although this is a large and arguably well powered study with independent replication, there are important limitations that should be considered. Of note is that the data used to derive polygenic scores do not presently fully account for all heritability attributable to common variation, nor do these measures reflect the contribution of rare variation and copy-number variants. In addition, the degree of variance explained by the SCZ-PGRS score for these phenotypes is relatively modest (0.5-1%). It should be considered however that they are consistent with other previously reported figures of 0-2% for similar phenotypes and in similarly unselected populationbased cohorts, and that the higher figures reported in the literature (7-18%) generally relate to the phenotype of SCZ case-control status (see (20)).
Another limitation relates to consistency of testing between these large datasets. Particularly relevant are the differences in administration of the tests of processing speed. Within GS:SFHS, a pen and paper version of the Digit Symbol Coding task from the Wechsler Adult Intelligence Scale III was used, where participants had a two minute time limit to complete the task. In UK Biobank the format of the task was a computerised version where the participant had to click on the number which matched the symbol shown and the participant had one minute to complete the test. Importantly, there were also fewer individuals included in the DSC assessments in UK Biobank 
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